Oxnard, CA- FOMAT Medical Research announced today the launch of our new Phase 1 capabilities. This expansion will enhance FOMAT’s ability to provide efficient and high-quality services to our clients in the pharmaceutical, medical device, and biotech industries
Our new extended capabilities will include new state-of-the-art facilities, specialized staff, and implementation of innovative technology. FOMAT will also now offer a full range of Phase 1 services, including early-phase clinical trials, pharmacokinetic and pharmacodynamic studies, and first-in-human trials.
Our clinic and site-specific processes are designed to carry out simple and complex clinical trials. Our clinical trial services also extend to the following areas: Infectious Diseases, Vaccines, CNS, Pain/HAP-HAL, Autoimmune, Inflammation, Metabolic, Endocrinology, NAFLD, NASH, Obesity, and T2D.
Working with us means you will benefit from our commitment to quality and efficiency. We will support you in achieving your clinical trial goals/objectives- and help advance your therapies to reach the market. This new launch marks a significant milestone in FOMAT’s ongoing commitment to innovate healthcare through diversity. Get in touch today to learn more about how we can help take your clinical trials to the next level!
About FOMAT Medical Research
FOMAT Medical Research, with more than 10 active locations, is a full-service Integrated Research Organization (IRO), focused on innovating healthcare through diversity. FOMAT, headquartered in Oxnard, California, brings over 10 years of experience in participating in Phase 1 through Phase 4 clinical trials in a wide variety of therapeutic areas. We rely on a highly experienced clinical research team with the professional expertise necessary to assist Sponsors and Contract Research Organizations (CROs) with reaching their project goals quickly and effectively.
If you want more information about our Phase 1 capabilities, please contact: